JP2019503985A5 - - Google Patents

Download PDF

Info

Publication number
JP2019503985A5
JP2019503985A5 JP2018522547A JP2018522547A JP2019503985A5 JP 2019503985 A5 JP2019503985 A5 JP 2019503985A5 JP 2018522547 A JP2018522547 A JP 2018522547A JP 2018522547 A JP2018522547 A JP 2018522547A JP 2019503985 A5 JP2019503985 A5 JP 2019503985A5
Authority
JP
Japan
Prior art keywords
hsc
composition
composition according
item
cell population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018522547A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019503985A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/060014 external-priority patent/WO2017079215A1/en
Publication of JP2019503985A publication Critical patent/JP2019503985A/ja
Publication of JP2019503985A5 publication Critical patent/JP2019503985A5/ja
Pending legal-status Critical Current

Links

JP2018522547A 2015-11-03 2016-11-02 モノクローナル抗体、造血幹細胞の産生のための方法および組成物、ならびにそれらを使用する方法 Pending JP2019503985A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562250424P 2015-11-03 2015-11-03
US62/250,424 2015-11-03
PCT/US2016/060014 WO2017079215A1 (en) 2015-11-03 2016-11-02 Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same

Publications (2)

Publication Number Publication Date
JP2019503985A JP2019503985A (ja) 2019-02-14
JP2019503985A5 true JP2019503985A5 (https=) 2019-12-12

Family

ID=57539587

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018522547A Pending JP2019503985A (ja) 2015-11-03 2016-11-02 モノクローナル抗体、造血幹細胞の産生のための方法および組成物、ならびにそれらを使用する方法

Country Status (6)

Country Link
US (1) US20180320136A1 (https=)
EP (1) EP3371222A1 (https=)
JP (1) JP2019503985A (https=)
CN (1) CN108350077A (https=)
CA (1) CA3002880A1 (https=)
WO (1) WO2017079215A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110755608A (zh) * 2018-07-27 2020-02-07 上海微创医疗器械（集团）有限公司 一种特异性抗体的用途、一种植入医疗器械及其制备方法
CN109053892B (zh) 2018-09-19 2021-03-26 苏州思坦维生物技术股份有限公司 特异结合人及猴cd38抗原的单克隆抗体及其制备方法与应用
US12319749B2 (en) 2019-02-01 2025-06-03 Sumitomo Chemical Company, Limited Antibody and functional fragment thereof
US20240075063A1 (en) * 2020-12-10 2024-03-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of mait cells for controlling graft versus host disease

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4965204A (en) 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
US5130144B1 (en) 1984-02-06 1995-08-15 Univ Johns Hopkins Human stem cells and monoclonal antibodies
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
FR2596413B1 (fr) 1986-03-27 1988-06-10 Merieux Inst Nouveaux milieux de culture de bacteries appartenant au genre bordetella, contenant des derives etherifies de polymeres de d-glucose, et leur application
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5536475A (en) 1988-10-11 1996-07-16 Baxter International Inc. Apparatus for magnetic cell separation
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5908782A (en) 1995-06-05 1999-06-01 Osiris Therapeutics, Inc. Chemically defined medium for human mesenchymal stem cells
US5965457A (en) * 1995-06-06 1999-10-12 Magnani; John L. Methods of screening for a candidate compound able to bind to CD34+ cells
US5719867A (en) 1995-06-30 1998-02-17 Scientific-Atlanta, Inc. Plural telephony channel baseband signal demodulator for a broadband communications system
WO1998021334A2 (en) * 1996-11-13 1998-05-22 Morphogenesis, Inc. Antibody mg1 recognizing a small subset of human hematopoietic cells
AU9508998A (en) * 1997-09-25 1999-04-12 Glycotech Corp. Methods and compositions for binding hematopoietic stem cells
EP1108011A2 (en) 1998-06-08 2001-06-20 Osiris Therapeutics, Inc. In vitro maintenance of hematopoietic stem cells
CZ302706B6 (cs) 1998-12-23 2011-09-14 Pfizer Inc. Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
EP2115460A4 (en) * 2007-01-18 2010-01-13 Suomen Punainen Risti Veripalv NEW CARBOHYDRATE FROM HUMAN CELLS AND METHOD FOR THE ANALYSIS AND MODIFICATION THEREOF
WO2008087259A1 (en) * 2007-01-18 2008-07-24 Suomen Punainen Risti, Veripalvelu Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
WO2009020201A1 (ja) * 2007-08-08 2009-02-12 Kyowa Hakko Kirin Co., Ltd. 単離された細胞集団
FI20070853A0 (fi) * 2007-11-09 2007-11-09 Glykos Finland Oy Glykaania sitovat monoklonaaliset vasta-aineet
WO2009070844A1 (en) * 2007-12-06 2009-06-11 Csl Limited Method of inhibition of leukemic stem cells
FI20095459A0 (fi) * 2009-04-24 2009-04-24 Suomen Punainen Risti Veripalv Uusia määritysmenetelmiä
US20120093782A1 (en) * 2009-05-13 2012-04-19 Grove Robert I Enhanced Hematopoietic Stem Cell Engraftment
WO2012039430A1 (ja) * 2010-09-21 2012-03-29 株式会社Ｇｐバイオサイエンス がん幹細胞の単離方法
FI20106031A0 (fi) * 2010-10-06 2010-10-06 Suomen Punainen Risti Veripalv Menetelmä solujen eristämiseksi ja menetelmällä eristetty solupopulaatio
US8464599B2 (en) 2011-01-10 2013-06-18 GM Global Technology Operations LLC Eight speed dual clutch transmission

Similar Documents

Publication Publication Date Title
Huang et al. Mesenchymal stem cells for prophylaxis of chronic graft-vs-host disease after haploidentical hematopoietic stem cell transplant: an open-label randomized clinical trial
Chitteti et al. CD166 regulates human and murine hematopoietic stem cells and the hematopoietic niche
JP6313219B2 (ja) Ｔ細胞／ｂ細胞枯渇化のための特異的プロトコルを使用する安定かつ長期の生着のための併用療法
Fabricius et al. Review on haploidentical hematopoietic cell transplantation in patients with hematologic malignancies
Michaelis et al. KIR haplotype B donors but not KIR-ligand mismatch result in a reduced incidence of relapse after haploidentical transplantation using reduced intensity conditioning and CD3/CD19-depleted grafts
JP2019503985A5 (https=)
CN101848991A (zh) 分离的细胞群
Wolpe et al. Hematopoietic stem cells
Ishibashi et al. ESAM is a novel human hematopoietic stem cell marker associated with a subset of human leukemias
Stroncek et al. Preliminary evaluation of a highly automated instrument for the selection of CD34+ cells from mobilized peripheral blood stem cell concentrates
Aoki et al. Allogeneic haematopoietic cell transplantation with reduced-intensity conditioning for elderly patients with advanced myelodysplastic syndromes: a nationwide study.
Alnasser et al. Autologous stem cell transplant in hodgkin’s and non-hodgkin’s lymphoma, multiple myeloma, and AL amyloidosis
JP2025072546A (ja) 血液疾患を治療するためのキット
Li et al. The effects of p38 MAPK inhibition combined with G-CSF administration on the hematoimmune system in mice with irradiation injury
AU2009255663B2 (en) Human facilitating cells
Kirschey et al. Rituximab combined with Dexa BEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B‐cell lymphoma: mature results of a phase II multicentre study
Mohty et al. Post-transplant cyclophosphamide or cell selection in haploidentical allogeneic hematopoietic cell transplantation?
Ruiz-Argüelles et al. Significance of one human leukocyte antigen mismatch on outcome of nonmyeloablative allogeneic stem cell transplantation from related donors using the Mexican schedule
Maqbool et al. Autologous hematopoietic stem cell transplantation conditioning regimens and chimeric antigen receptor T cell therapy in various diseases
Konuma et al. Radiation‐free myeloablative conditioning consisting of fludarabine added to full‐dose busulfan and cyclophosphamide in single‐unit cord blood transplantation for adults.
Higuchi et al. Separation of CD34+ cells from human peripheral blood through polyurethane foaming membranes
Yamamoto et al. Soluble interleukin-2 receptor level at diagnosis predicts prognosis of patients with follicular lymphoma irrespective of initial management strategy
JP2010508854A5 (https=)
Trigg Milestones in the development of pediatric hematopoietic stem cell transplantation—50 years of progress
Courville et al. Impending relapse of myelodysplastic syndrome after allogeneic transplant is difficult to diagnose and requires a multi-modal approach